NASDAQ:GERN
Geron Corporation Stock News
$3.73
-0.200 (-5.09%)
At Close: May 06, 2024
Endo (ENDP) Phase II Study for Frozen Shoulder Disappoints
03:43pm, Monday, 04'th Jul 2022 Zacks Investment Research
Endo (ENDP) mid-stage study of collagenase clostridium histolyticum (or CCH) for treating frozen shoulder disappoints.
Best Penny Stocks To Watch? 4 For Your Independence Day List
07:04pm, Friday, 01'st Jul 2022 PennyStocks
Penny stocks to watch right now
The post Best Penny Stocks To Watch? 4 For Your Independence Day List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks To Watch? 4 For Your Independence Day List
03:04pm, Friday, 01'st Jul 2022
Penny stocks to watch right now The post Best Penny Stocks To Watch? 4 For Your Independence Day List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Novartis (NVS) Announces Positive Data on Oncology Drug
03:01pm, Friday, 01'st Jul 2022 Zacks Investment Research
Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.
Hot Penny Stocks That Are Climbing Right Now
12:11am, Thursday, 30'th Jun 2022 PennyStocks
Can these penny stocks climb this week?
The post Hot Penny Stocks That Are Climbing Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Hot Penny Stocks That Are Climbing Right Now
08:11pm, Wednesday, 29'th Jun 2022
Can these penny stocks climb this week? The post Hot Penny Stocks That Are Climbing Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
02:28pm, Wednesday, 29'th Jun 2022 Zacks Investment Research
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Trending Penny Stocks For Your Watchlist Next Month
12:25am, Wednesday, 29'th Jun 2022 PennyStocks
Here are three penny stocks to watch this week
The post Trending Penny Stocks For Your Watchlist Next Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Trending Penny Stocks For Your Watchlist Next Month
08:25pm, Tuesday, 28'th Jun 2022
Here are three penny stocks to watch this week The post Trending Penny Stocks For Your Watchlist Next Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
12:49pm, Tuesday, 28'th Jun 2022 Zacks Investment Research
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.
Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation
05:21pm, Monday, 27'th Jun 2022 Zacks Investment Research
Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.
Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion
05:06pm, Monday, 27'th Jun 2022 Zacks Investment Research
Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.
Radius (RDUS) to Go Private With $890M Deal, Shares Gain
05:13pm, Friday, 24'th Jun 2022 Zacks Investment Research
Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.
Gilead (GILD) Announces Positive Data on Hepcludex for HDV
04:30pm, Friday, 24'th Jun 2022 Zacks Investment Research
Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.
Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug
05:18pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.
